Michael Petusky

Stock Analyst at Barrington Research

(2.26)
# 2,702
Out of 5,129 analysts
222
Total ratings
40.5%
Success rate
-2.41%
Average return

Stocks Rated by Michael Petusky

Bioventus
Feb 9, 2026
Initiates: Outperform
Price Target: $13
Current: $8.07
Upside: +61.09%
Haemonetics
Feb 6, 2026
Maintains: Outperform
Price Target: $93$94
Current: $59.46
Upside: +58.09%
Option Care Health
Jan 16, 2026
Maintains: Outperform
Price Target: $38$42
Current: $33.15
Upside: +26.70%
Anika Therapeutics
Jan 9, 2026
Maintains: Outperform
Price Target: $16
Current: $10.33
Upside: +54.89%
VerifyMe
Jan 6, 2026
Maintains: Outperform
Price Target: $1$1.5
Current: $1.05
Upside: +42.86%
U.S. Physical Therapy
Jan 5, 2026
Maintains: Outperform
Price Target: $103
Current: $85.41
Upside: +20.59%
DENTSPLY SIRONA
Jan 5, 2026
Maintains: Outperform
Price Target: $14
Current: $13.93
Upside: +0.50%
Merit Medical Systems
Nov 14, 2025
Maintains: Outperform
Price Target: $106
Current: $82.22
Upside: +28.92%
Henry Schein
Nov 5, 2025
Maintains: Outperform
Price Target: $78$79
Current: $81.04
Upside: -2.51%
Orthofix Medical
Nov 5, 2025
Maintains: Outperform
Price Target: $17$18
Current: $13.37
Upside: +34.63%
Maintains: Outperform
Price Target: $2.25
Current: $1.22
Upside: +84.43%
Maintains: Outperform
Price Target: $95
Current: $87.98
Upside: +7.98%
Downgrades: Market Perform
Price Target: n/a
Current: $7.38
Upside: -